Aggressive coronary artery vasculopathy after combined heart-lung transplantation.
Combined heart-lung transplantation remains as a treatment option for patients with cardiopulmonary failure. There is speculation that lung grafts protect the heart from developing graft vasculopathy after combined heart-lung transplantation. This protective mechanism is more likely, at best, a delay in the onset of coronary artery vasculopathy. We present our experiences in two cases of an aggressive form of cardiac allograft vasculopathy after combined heart-lung transplantation that resulted in the death of both patients.
Nationwide Children's Hospital The Ohio State University College of Medicine, Columbus, OH 43205, USA. hayes.705@osu.edu
Don
D
Hayes
Peter B
PB
Baker
Todd L
TL
Astor
Thomas J
TJ
Preston
Stephen
S
Kirkby
Mark
M
Galantowicz
Timothy M
TM
Hoffman
D000328:Adult; D001706:Biopsy; D001989:Bronchiolitis Obliterans / Q000209:etiology; D002317:Cardiovascular Agents / Q000627:therapeutic use; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D017809:Fatal Outcome; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000209:etiology; D006330:Heart Defects, Congenital / Q000601:surgery*; D016041:Heart-Lung Transplantation / Q000009:adverse effects*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
D002317:Cardiovascular Agents; D007166:Immunosuppressive Agents